1. Use of liposomal nanoformulations in antileishmania therapy: challenges and perspectives.
- Author
-
Téllez, Jair, Echeverry, Maria Clara, Romero, Ibeth, Guatibonza, Andrea, Santos Ramos, Guilherme, Borges De Oliveira, Ana Carolina, Frézard, Frédéric, and Demicheli, Cynthia
- Subjects
- *
CUTANEOUS leishmaniasis , *SCIENTIFIC literature , *DRUG delivery systems , *PARASITIC diseases , *DRUG utilization , *NANOMEDICINE , *LEISHMANIASIS - Abstract
Leishmaniasis is a parasitic disease treatable and curable, however, the chemotherapeutic agents for their treatment are limited. In South American countries, pentavalent antimonials are still the first line of treatment for cutaneous leishmaniasis with an efficacy of about 75%, but the toxicity of the drug causes serious side effects and remains as the main obstacle for treatment. New knowledge aimed to improve drug delivery into the intracellular environment is essential, especially for drugs currently used in the clinic, to develop new anti-Leishmania formulations. In the present study, we analysed the scientific literature to highlight the progress achieved in the last decade regarding the use of nanotechnology for improving the current leishmaniasis treatments. Results allowed us to conclude that the encapsulated Glucantime liposomal formulation can be improved by means of nanoparticle functionalization processes, resulting in new drug delivery systems that can be potentially proposed as alternative therapies for leishmaniasis treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF